Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IL-31 mAB
BMS-981164 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.1 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.01 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.03 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.06 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.1 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.3 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 1 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 1 mg/kg solution intravenously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously |
| Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 3 mg/kg solution intravenously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously |
| Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 10.0 mg/kg solution intravenously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously |
| Dose Escalation- BMS-981164 or Placebo (dose group 1) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose |
| Dose Escalation- BMS-981164 or Placebo (dose group 2) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose |
| Dose Escalation- BMS-981164 or Placebo (dose group 3) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose |
| Dose Escalation- BMS-981164 or Placebo (dose group 4) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and \>1.0mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose |
| Name | Type | Description |
|---|---|---|
| BMS-981164 | BIOLOGICAL | - |
| Placebo matching with BMS-981164 | BIOLOGICAL | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Part 1: Healthy subjects * Part 2: Adult subjects with: 1. Atopic dermatitis severity as assessed by Physician Global Assessment rating of 3 or higher (i.e., moderate or g...
BMS-981164 is an investigational monoclonal antibody developed by Bristol-Myers Squibb Company (ticker BMY). It was studied as an anti-interleukin 31 monoclonal antibody in a Phase 1 clinical trial that enrolled healthy volunteers and adults with atopic dermatitis. The study has been completed, and the program remains in early-stage clinical development.
BMS-981164 targets interleukin 31, or IL-31. It is an anti-interleukin 31 monoclonal antibody, meaning it is designed to bind IL-31. The Phase 1 study of BMS-981164 was titled as a study of an IL-31 monoclonal antibody in healthy subjects and adults with atopic dermatitis.
Bristol-Myers Squibb Company, which trades under the ticker BMY, is the developer of BMS-981164. The company sponsored the Phase 1 study of the anti-interleukin 31 monoclonal antibody conducted in the United Kingdom.
BMS-981164 is in Phase 1 development. It is an investigational monoclonal antibody and is not described as approved. Its only recorded trial, NCT01614756, was a Phase 1 study that has been completed, and no active trials are currently listed for the asset.
BMS-981164 was evaluated in one clinical trial, NCT01614756, titled a two-part Phase 1 single-dose study of an IL-31 monoclonal antibody in healthy subjects and adults with atopic dermatitis. The trial was completed, enrolled 93 participants, was randomized, double-blind, and controlled, and was conducted in the United Kingdom.